Genetic Testing in Patients with Arrhythmia and Risk for Sudden Cardiac Death : Indications and Implications for Practice Mary Gertrude Ong-Cordovez, M.D.

Slides:



Advertisements
Similar presentations
LQTS Outline Background Identification Therapies Available
Advertisements

Brugada Patient and the Environment: Harmful Factors and Drugs
Management of the Patient Presenting with Wide Complex Tachycardia
Long QT and Jervell & Lange-Nielsen. Long QT syndrome (LQT) Disease of heart electrophysiology.
Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.
Brugada’s Syndrome and Sudden Cardiac Death
Ventricular Tachycardia
April 1 st, 2013 Heart Failure Education Series David N. Edwards, M.D. Ph.D. F.A.C.C. Advanced Heart Care, PA The Heart Hospital Baylor Plano.
DOMENICO CORRADO, MD, PhD University of Padova, Italy
Hypertrophic Cardiomyopathy Guidelines Summary from the: ACC/ESC Clinical Expert Consensus Statement on Hypertrophic Cardiomyopathy Maron BJ, et al. J.
Brugada Syndrome Carly Thompson MD CCFP EM Resident July 31, 2008.
Hypertrophic Cardiomyopathy Developed by Dr. Judith Allanson, Ms. Shawna Morrison and Dr. June Carroll Last updated Jan 2015.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
Thursday 4/12/2014 Hassan Alahmadi Medical Resident ( R1)
Overlapping genetic syndromes Ramon Brugada Director, Centre de Genètica Cardiovascular IDIBGI Cardiologist, Hospital Josep Trueta Dean, School of Medicine,
Coronary Artery Disease Megan McClintock. Coronary Artery Disease Definition Etiology/Pathophysiology Risk Factors –Unmodifiable –Modifiable Signs & symptoms.
Syncope AM Report 6/25/10 Nicole Wilde. Syncope  Cause Not Obvious Neurally Mediated (vasovagal) 58% Cardiac Disease (arrhythmias) 23% Neurologic or.
 Genetic disease of heart muscle characterized by left ventricular hypertrophy in absence of another cardiac or systemic disease; variable morphologies.
Heart Failure John Lynn Jefferies, MD, MPH, FAAP, FACC Director, Cardiomyopathy, Advanced Heart Failure, and Ventricular Assist Device Programs Co-Director,
Although rare, there have been reported cases of antihistamine, cocaine, and psychotropic drug induced Brugada Syndrome. Loperamide is another agent that.
The EP show: Brugada Syndrome Eric Prystowsky, MD Director
Management of the Patient Presenting with Palpitation Samir Saba, MD Director, Cardiac Electrophysiology University of Pittsburgh.
Prof. N. Sudhaya Kumar, AIMS, Cochin. Primary cardiomyopathies Genetic HCM ARVD LV noncompaction Mitochondral myopathy Glyc.storage dis. channelopathies.
Ventriclar Tachycardia
Clinical Teaching Case Anthony Battad MD, FRCPC University of Manitoba.
A typical day at work October 29 th, So, you get to work, and go to see your first patient… 21-year-old female with a history of "seizure" disorder.
BIMM118 Cardiac Arrhythmia Arrhythmias : Abnormal rhythms of the heart that cause the heart to pump less effectively Arrhythmia occurs: –when the heart’s.
汪道武 南京医科大学第一附属医院心脏科 江苏省人民医院 江苏省心肺疾病研究所 2012 年 9 月 15 日 中华医学会心电生理和起搏分会第十次年会 汪道武 南京医科大学第一附属医院心脏科 江苏省人民医院 江苏省心肺疾病研究所 2012 年 9 月 15 日 中华医学会心电生理和起搏分会第十次年会 SCN5A.
An Electrical Storm 9 th May 2014 U Buckley, D Eaton, J Galvin, T Keelan Mater Misericordiae Hospital, Dublin.
Tachyarrhythmia Gaurav Panchal. Arrhythmogenesis Impulse formation –Automaticity – inappropriate Tachy / brady; accelerated Ventricular rate after MI.
By Mahmoud Shah Professor of cardiology Zagazig university
ICD Indications T he Guidelines and Beyond University of Minnesota Medical Center Fei Lü, M.D., Ph.D., F.A.C.C., F.H.R.S. Associate Professor of Medicine.
William M. Miles, MD, FHRS University of Florida College of Medicine Gainesville, FL ICD Implantation: Genetic Arrhythmia Syndromes.
The Electrical Management of Cardiac Rhythm Disorders Tachycardia Indications for ICD Implantation.
Treatment of hypertrophic obstructive cardiomyopathy with alcohol ablation Kulić M., Spužić M., Tahirović E., Mujačić V., Šošević A., Perva O., Ćibo M.,
Valvular Heart Disease
ECG etc… (Miscellaneous ECGs) Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.
ECG Workshop in Cardiac Ion Channel Diseases Dr. Ngai-Shing Mok Dept of Medicine & Geriatrics Princess Margaret Hospital Hong Kong.
Jenny Taylor Oxford Genetics Knowledge Park Wellcome Trust Centre for Human Genetics, Oxford, UK Genomics and Population Health 26 th January 2006.
Consultant Cardiologist
IN THE NAME OFGODIN THE NAME OFGOD SVTS.SAYAH.  All cardiac tachyarrhythmias are produced by: 1/disorders of impulse initiation :automatic 2/abnormalities.
THE HEART’S ELECTRICAL SYSTEM Marco Perez, MD Center for Inherited Cardiovascular Disease Inherited Cardiac Arrhythmia Clinic June 20, 2013.
L ONG QT SYNDROME Katie DePlatchett, M.D. AM Report April 7, 2010.
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
“I Need This Form Filled Out”: Pediatric Sports Physical Assessment Aaron T Dorfman, MD Pediatric Cardiology New Jersey Section The Children’s Hospital.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prevalence and Characteristics of Early Repolarization.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pre-Participation Screening of Young Competitive.
Long QT Syndrome Developed by Ms. Shawna Morrison, Dr. Judith Allanson and Dr. June Carroll Last updated October 2016.
Hypertrophic Cardiomyopathy
Cardiomyopathies Pavol Tomašov.
Ethical Scenario: Cardiovascular System
Disclosures None.
Induced Brugada Syndrome - what are the risks?
Implantable Defibrillator Therapy Post Cardiac Arrest
Brugada’s Syndrome and Sudden Cardiac Death
Echocardiograms in syncope work-up
Molecular Determinants of Na+ and K+ Channel Regulation in Heart: Ion Channels as Targets of Neurohormones and Drugs.
Hypertrophic Cardiomyopathy
Arrhythmogenic right ventricular dysplasia
Developed in Collaboration With The American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,
HYPERTROPHIC CARDIOMYOPATHY(HCM)
Dirty Laundry.
Syncope in children.
Volume 9, Issue 1, Pages (January 2012)
Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,
Genetics made easy: demystifying genetic testing
Andrew D. Krahn, MD, Shubhayan Sanatani, MD, Martin J
Diagnosis at presentation and diagnoses finally reached at the end of the inpatient admission. Diagnosis at presentation and diagnoses finally reached.
Jeffrey B. Geske et al. JCHF 2018;j.jchf
Presentation transcript:

Genetic Testing in Patients with Arrhythmia and Risk for Sudden Cardiac Death : Indications and Implications for Practice Mary Gertrude Ong-Cordovez, M.D. Cebu City

Inherited Cardiac Arrhythmias Channelopathy (ion channel disease) LQTS CPVT Brugada Syndrome Primary Structural Heart Disease (cardiomyopathies) ARVC/D HOCM Familial DCM

Epidemiology 1:500 (HOCM) 1:1000(ARVD) 1:2000 (LQTS, CPVT, Brugada syndrome) 1:2500 (DCM)

Ion Channel Diseases LQTS: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2 (65%) Brugada syndrome: SCN5A (25% to 30%) CPVT: RYR2 (60%), possibly CASQ2

Cardiomyopathies ARVD: PKP2, DSP, DSG2 (60%) HOCM: MYH7, MYBPC3, TNNT2 (60%) DCM: LMNA, MYH7, TNNT2, SCN5A (20% to 30%)

LQTS

Genotype-phenotype correlations in long-QT syndrome. Tester D J, Ackerman M J Circulation 2011;123: Copyright © American Heart Association

LQTS Management Beta Blockers Mexilitene, flecainide, propanolol Treat hypokalemia and hypomagnesemia ICD Avoid QT prolonging drugs

QT Prolonging Drugs Albuterol epinephrineroxithromycin Alfuzosin erythromycinsalmeterol Amiodarone famotidinesertraline Amphetamine flecainidesotalol Azithromycin gatifloxacintamoxifen Ciprofoxacin imipramineterbutaline Clarythhromycin ketoconazoleSXT Diphenhydramin levofloxacinvardenafil Dobutamine moxifloxacin Dopamine ofloxacin

Ion Channel Diseases LQTS: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2 (65%) Brugada syndrome: SCN5A (25% to 30%) CPVT: RYR2 (60%), possibly CASQ2 ARVD: PKP2, DSP, DSG2 (60%)

Recommendations for Genetic Testing Cardiac arrest survivor++ Syncope QTc abnormal ++ QTc borderline +/- QTc normal _ Asymptomatic QTc abnormal++ QTc borderline _ First degree relative Proband genotype + ++ Proband genotype _ _ Canadian J of Cardiology 27(2011)

Brugada Syndrome

Management Beta blocker and amiodarone Quinidine Aggressive fever control Avoid strenuous physical activity ICD Avoid sodium channel blocker

Na Channel Blockers Anti-arrhythmic drugs Flecainide, propafenone, ajmalin, procainamide Psychotropic Drugs Amitriptyline, lithium, nortriptyline, trifluoperazine Anesthetics/Analgesics Bupivacaine, procaine, profolol Others Acetylcholine, alcohol, cocaine, ergonovine

Ion Channel Diseases LQTS: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2 (65%) Brugada syndrome: SCN5A (25% to 30%) CPVT: RYR2 (60%), possibly CASQ2

Recommendations for Genetic Testing (Brugada Syndrome) Cardiac arrest survivor Type I Brugada ECG pattern++ Type 2 or 3 ECG pattern __ Syncope Type I Brugada ECG pattern++ Type 2 or 3 ECG pattern __ Asymptomatic Type I Brugada ECG pattern++ Type 2 or 3 ECG pattern__ First Degree Relative Proband genotype positive++ Proband genotype negative ___

CPVT

Management Beta blockers Flecainide/cardiac sympathectomy ICD Avoid intense physical exercise

Ion Channel Diseases LQTS: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2 (65%) Brugada syndrome: SCN5A (25% to 30%) CPVT: RYR2 (60%), possibly CASQ2

Recommendations for Genetic Testing (CPVT) Clinically suspected CPVT++ First degree relative Proband genotype +++

ARVD/C Task Force Criteria RV function Tissue characteristic of the myocardium ECG repolarization abnormalities Arrhythmias Family history Genetic testing

ARVD Management Avoid competitive sports ICD Documented ventricular arrhythmias

Cardiomyopathies ARVD: PKP2, DSP, DSG2 (60%-70%) HOCM: MYH7, MYBPC3, TNNT2 (60%) DCM: LMNA, MYH7, TNNT2, SCN5A (20% to 30%)

Recommendations for Genetic Testing (ARVD) Clinical ARVD ++ Clincal ARVD no ID at risk family members__ Clinically suspected ARVD++ First degree relative Genotype positive++ Genotype negative__

HOCM Echocardiography MRI

Management Asymptomatic Treat risk factors- HPN, DM, dyslipidemia, obesity Beta-blockers Angina and dyspnea verapamil Septal reduction Rx surgical septal myectomy/ alcohol septal ablation Drug refractory and LVOT obstruction ICD

Indications for ICDs in HCM. *SCD risk modifiers include established risk factors and emerging risk modifiers (Section 9.4.2). et al. Circulation 2011;124: Copyright © American Heart Association

Management Asymptomatic Treat risk factors- HPN, DM, dyslipidemia, obesity Beta-blockers Angina and dyspnea verapamil Septal reduction Rx surgical septal myectomy/ alcohol septal ablation Drug refractory and LVOT obstruction ICD Exercise restriction

HOCM Exercise Permitted Bowling, brisk walking, golf, skating, snorkeling, treadmill, biking Strongly discouraged Basketball, body building, rock climbing, sprinting, soccer, tennis, wind surfing, scuba diving Circulation 2011;124:

Cardiomyopathies ARVD: PKP2, DSP, DSG2 (60%-70%) HOCM: MYH7, MYBPC3, TNNT2 (60%) DCM: LMNA, MYH7, TNNT2, SCN5A (20% to 30%)

Recommendationf for Genetic Testing (HOCM) Clinically diagnose HOCM Family screening++ Diagnosis__ Risk stratification/Rx decisions __

DCM Cardiac imaging studies Cardiac biopsy- diagnostic tool Management ACEI, B blockers, spironolactone ICD - EF <35% Biventricular pacing

Cardiomyopathies ARVD: PKP2, DSP, DSG2 (60%-70%) HOCM: MYH7, MYBPC3, TNNT2 (60%) DCM: LMNA, MYH7, TNNT2, SCN5A (20% to 30%)

Recommendation for Genetic Testing (DCM) Clinically Dx DCM__ Clinically Dx DCM w/ atrial arrhythmias/high grade conduction disease++ (LMNA, SCNA5)

Future Perspective Gene sequencing will be faster and available more cheaply Multidisciplinary approach Gray areas Gene therapy